Adalimumab Experience in the Management of Hidradenitis Suppurativa Burdened with Rapp-Hodgkin Syndrome

Background. Rapp-Hodgkin syndrome is a rare genetic disease from the ectodermal dysplasia group. It manifests with damage of ectodermal structures — layer of embrional tissue that provides the development of many organs and tissues in the body, such as: skin, sweat glands, hair, teeth, and nails. Disease symptoms may range from mild to severe and include dental abnormalities, fragile, thin or no hair, abnormal nails, hypohidrosis (due to the reduced number of sweat glands), cleft lips and palate. Hidradenitis suppurativa is a chronic inflammatory disease that predominantly affects apocrine glands areas. This nosology is characterized by painful nodes, abscesses, and fistulas, prone to relapses and leading to scarring.

Clinical case description. The authors present a clinical case demonstrating the combination of Rapp-Hodgkin syndrome and severe hidradenitis suppurativa in 17-year-old male patient.

Conclusion. The heterogeneous clinical findings of hidradenitis suppurativa and history of rare genetic disease result in patients' admissions to various medical specialists. Thus, it leads to delayed verification of the diagnosis and incorrect treatment methods. As a result, patients have persistent cosmetic skin defects, possible complications of irrational treatment, and decreased quality of life by the time of diagnosis.

1. Morrell DS, Burkhart CN, Siegel D. Chapter 26 — Selected Hereditary Diseases. In: Neonatal Dermatology. Eichenfield LF, Frieden IJ, Esterly NB, eds. 2nd ed. W.B. Saunders; 2008. pp. 477–501. doi: https://doi.org/10.1016/B978-1-4160-3432-2.50029-7

2. Chatterjee M, Neema S, Mukherjee S. Rapp Hodgkin Syndrome. Indian Dermatol Online J. 2017;8(3):215–216. doi: https://doi.org/10.4103/idoj.IDOJ_100_16

3. Brueggemann FB, Bartsch O. A recurrent TP63 mutation causing EEC3 and Rapp-Hodgkin syndromes. Clin Dysmorphol. 2016;25(2):50–53. doi: https://doi.org/10.1097/MCD.0000000000000117

4. Schmidt J, Schreiber G, Altmüller J, et al. Familial cleft tongue caused by a unique translation initiation codon variant in TP63. Eur J Hum Genet. 2022;30(2):211–218. doi: https://doi.org/10.1038/s41431-021-00967-x

5. Khandelwal KD, van den Boogaard MH, Mehrem SL, et al. Deletions and loss-of-function variants in TP63 associated with orofacial clefting. Eur J Hum Genet. 2019;27(7):1101–1112. doi: https://doi.org/10.1038/s41431-019-0370-0

6. Majmundar VD, Baxi K. Ectodermal Dysplasia. 2022 Jul 25. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.

7. Wawrzycki B, Pietrzak A, Chodorowska G, et al. Ectrodactylyectodermal dysplasia-clefting syndrome with unusual cutaneous vitiligoid and psoriasiform lesions due to a novel single point TP63 gene mutation. Postepy Dermatol Alergol. 2019;36(3):358–364. doi: https://doi.org/10.5114/ada.2018.73437

8. Akter S, Hossain S, Ali MA, et al. Comprehensive Characterization of the Coding and Non-Coding Single Nucleotide Polymorphisms in the Tumor Protein p63 (TP63) Gene Using In Silico Tools. Biomolecules. 2021;11(11):1733. doi: https://doi.org/10.3390/biom11111733

9. Nanda A, AlLafi A, Wolf S, et al. TP63-related disorders: two case reports and a brief review of the literature. Dermatol Online J. 2021;27(11). doi: https://doi.org/10.5070/D3271156088

10. Kirby B, Caird A, Rogers S. Intolerance of isotretinoin in a patient with anhidrotic ectodermal dysplasia. Br J Dermatol. 1999;141(1): 175. doi: https://doi.org/10.1046/j.1365-2133.1999.02954.x

11. Zabel J, Dańczak D. Case of ectodermal dysplasia with maintained function of sweat glands and extensive acne. Przegl Dermatol. 1977;64(6):725–728.

12. Musumeci ML, Fiorentini F, Bianchi L, et al. Follicular occlusion tetrad in a male patient with pachyonychia congenita: clinical and genetic analysis. J Eur Acad Dermatol Venereol. 2019;33 Suppl 6:36–39. doi: https://doi.org/10.1111/jdv.15851

13. Chen W, Plewig G. Should hidradenitis suppurativa/acne inversa best be renamed as “dissecting terminal hair folliculitis”? Exp Dermatol. 2017;26(6):544–547. doi: https://doi.org/10.1111/exd.13211357

14. Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2020;82(5):1045–1058. doi: https://doi.org/10.1016/j.jaad.2019.08.090

15. Ingram JR. Hidradenitis suppurativa: an update. Clin Med. 2016; 16(1):70–73. doi: https://doi.org/10.7861/clinmedicine.16-1-70

16. Onderdijk AJ, van der Zee HH, Esmann S, et al. Depression in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2013;27(4):473–478. doi: https://doi.org/10.1111/j.1468-3083.2012.04468.x

17. Delany E, Gormley G, Hughes R, et al. A cross-sectional epidemiological study of hidradenitis suppurativa in an Irish population (SHIP). J Eur Acad Dermatol Venereol. 2018;32(3): 467–473. doi: https://doi.org/10.1111/jdv.14686

18. Saunte DM, Boer J, Stratigos A, et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol. 2015;173(6):1546–1549. doi: https://doi.org/10.1111/bjd.14038

19. Aroonsakul N, Phinyo P, Lumkul L, et al. Pharmacological interventions for hidradenitis suppurativa: a protocol for systematic review and network meta-analysis of randomised trials and non-randomised studies. BMJ Open. 2022;12(9):e062351. doi: https://doi.org/10.1136/bmjopen-2022-062351

20. Liy-Wong C, Pope E, Lara-Corrales I. Hidradenitis suppurativa in the pediatric population. J Am Acad Dermatol. 2015;73(5 Suppl 1): S36–S41. doi: https://doi.org/10.1016/j.jaad.2015.07.051

21. Tiri H, Jokelainen J, Timonen M, et al. Somatic and psychiatric comorbidities of hidradenitis suppurativa in children and adolescents. J Am Acad Dermatol. 2018;79(3):514–519. doi: https://doi.org/10.1016/j.jaad.2018.02.067

22. Sachdeva M, Kim P, Mufti A, et al. Biologic Use in Pediatric Patients With Hidradenitis Suppurativa: A Systematic Review. J Cutan Med Surg. 2022;26(2):176–180. doi: https://doi.org/10.1177/12034754211049711

23. Tsai YC, Hung CY, Tsai TF. Efficacy and Safety of Biologics and Small Molecules for Moderate-to-Severe Hidradenitis Suppurativa: A Systematic Review and Network Meta-Analysis. Pharmaceutics. 2023;15(5):1351. doi: https://doi.org/10.3390/pharmaceutics15051351

24. Koguchi-Yoshioka H, Wataya-Kaneda M, Yutani M, et al. Atopic diathesis in hypohidrotic/anhidrotic ectodermal dysplasia. Acta Derm Venereol. 2015;95(4):476–479. doi: https://doi.org/10.2340/00015555-1978

25. Vossen ARJV, Ardon CB, van der Zee HH, et al. The antiinflammatory potency of biologics targeting tumour necrosis factor, interleukin (IL)-17A, IL-12/23 and CD20 in hidradenitis suppurativa: an ex vivo study. Br J Dermatol. 2019;181(2):314–323. doi: https://doi.org/10.1111/bjd.17641

26. Scheinfeld N. Hidradenitis suppurativa: A practical review of possible medical treatments based on over 350 hidradenitis patients. Dermatol Online J. 2013;19(4):1.

27. Saunte DML, Jemec GBE. Hidradenitis Suppurativa: Advances in Diagnosis and Treatment. JAMA. 2017;318(20):2019–2032. doi: https://doi.org/10.1001/jama.2017.16691

28. Khobeish MM, Shustov DV, Sokolovsky EV. Hidradenitis Suppurativa: Modern Concepts of Pathogenesis and Therapy; Successful Experience of Adalimumab Therapy. Vestnik Dermatologii i Venerologii. 2017;(5):70–81. (In Russ). doi: https://doi.org/10.25208/ 0042-4609-2017-93-5-70-81

29. Bahillo Monné C, Honorato Guerra S, Schoendorff Ortega C, Gargallo Quintero AB. Management of hidradenitis suppurativa with biological therapy: report of four cases and review of the literature. Dermatology. 2014;229(4):279–287. doi: https://doi.org/10.1159/000365076